Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 Jan;61(1):32–36. doi: 10.1136/ard.61.1.32

Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice

B Gudbjornsson 1, U Juliusson 1, F Gudjonsson 1
PMCID: PMC1753894  PMID: 11779755

Abstract

Background: The use of oral corticosteroids (CS) is one of the most common causes of iatrogenic osteoporosis. Recently, therapeutic guidelines dealing with the skeletal complication of CS have been published.

Objective: To evaluate how CS are used in the community and the frequency of active intervention against corticosteroid induced osteoporosis in daily clinical practice.

Material and methods: After approval by the Committee on Medical Ethics and the Data Protection Commission all prescriptions for CS which were filled by pharmacies in the northeast area of Iceland (population 26 664) during a two year period were collected. Thereafter, clinical information was obtained from medical records at the healthcare centres and from the local hospital. Patients who were taking CS for at least three months a year or for repeated periods (for a total of three months annually) were included in the study. These patients also received a questionnaire about hormone replacement therapy, bisphosphonates, and dietary consumption of calcium and vitamin D.

Results: A total of 191 patients were included in the study or 0.7% of the population. Their mean age was 66 years (17–93) and 106/191 (55%) were women. Only 63 (33%) patients had no registered complication due to the treatment, according their medical records. Thirty nine (20%) patients had had an osteoporosis related fracture and 50 (26%) of the patients had presumed CS induced osteoporosis. A total of 52% patients were receiving supplementary vitamin D (fish liver oil) and 37% were taking calcium tablets regularly, while 91% of the patient group were consuming milk products regularly. Only 17 (9%) patients were taking bisphosphonates and 18/81 (22%) of the postmenopausal women were receiving hormone replacement therapy.

Conclusions: Relatively few patients receiving long term treatment with CS are also receiving primary prevention against CS induced osteoporosis, although several patients are taking vitamin D and calcium tablets. Specific treatment against osteoporosis was in most cases instituted secondary to osteoporotic complications. Thus although there are available treatment alternatives against CS induced osteoporosis, the doctors who prescribed CS did not make use of this form of treatment for their patients.

Full Text

The Full Text of this article is available as a PDF (110.8 KB).

Figure 1 .

Figure 1

Open in a new tab

Age and sex distribution of 191 patients taking continuous oral corticosteroids for at least three months.

Figure 2 .

Figure 2

Open in a new tab

Duration in years of continuous oral corticosteroid treatment in 163 patients. The length of time was calculated from the start of the treatment to the end of the treatment or to the date of the study.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi J. D., Bensen W. G., Bianchi F., Cividino A., Pillersdorf S., Sebaldt R. J., Tugwell P., Gordon M., Steele M., Webber C. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol. 1996 Jun;23(6):995–1000. [PubMed] [Google Scholar]
  2. Adachi J. D., Bensen W. G., Brown J., Hanley D., Hodsman A., Josse R., Kendler D. L., Lentle B., Olszynski W., Ste-Marie L. G. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997 Aug 7;337(6):382–387. doi: 10.1056/NEJM199708073370603. [DOI] [PubMed] [Google Scholar]
  3. Adinoff A. D., Hollister J. R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 1983 Aug 4;309(5):265–268. doi: 10.1056/NEJM198308043090502. [DOI] [PubMed] [Google Scholar]
  4. Blair M. M., Carson D. S., Barrington R. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis. J Fam Pract. 2000 Sep;49(9):839–848. [PubMed] [Google Scholar]
  5. Boumpas D. T., Chrousos G. P., Wilder R. L., Cupps T. R., Balow J. E. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993 Dec 15;119(12):1198–1208. doi: 10.7326/0003-4819-119-12-199312150-00007. [DOI] [PubMed] [Google Scholar]
  6. Center J. R., Nguyen T. V., Schneider D., Sambrook P. N., Eisman J. A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999 Mar 13;353(9156):878–882. doi: 10.1016/S0140-6736(98)09075-8. [DOI] [PubMed] [Google Scholar]
  7. Cooper C., Atkinson E. J., Jacobsen S. J., O'Fallon W. M., Melton L. J., 3rd Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993 May 1;137(9):1001–1005. doi: 10.1093/oxfordjournals.aje.a116756. [DOI] [PubMed] [Google Scholar]
  8. Dolan P., Torgerson D. J. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int. 1998;8(6):611–617. doi: 10.1007/s001980050107. [DOI] [PubMed] [Google Scholar]
  9. Eastell R. Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. J Intern Med. 1995 May;237(5):439–447. doi: 10.1111/j.1365-2796.1995.tb00868.x. [DOI] [PubMed] [Google Scholar]
  10. Eastell R., Reid D. M., Compston J., Cooper C., Fogelman I., Francis R. M., Hosking D. J., Purdie D. W., Ralston S. H., Reeve J. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998 Oct;244(4):271–292. doi: 10.1046/j.1365-2796.1998.00408.x. [DOI] [PubMed] [Google Scholar]
  11. Goulding A., Gold E. Effects of chronic prednisolone treatment on bone resorption and bone composition in intact and ovariectomized rats and in ovariectomized rats receiving beta-estradiol. Endocrinology. 1988 Feb;122(2):482–487. doi: 10.1210/endo-122-2-482. [DOI] [PubMed] [Google Scholar]
  12. Hahn T. J. Drug-induced disorders of vitamin D and mineral metabolism. Clin Endocrinol Metab. 1980 Mar;9(1):107–127. doi: 10.1016/s0300-595x(80)80023-5. [DOI] [PubMed] [Google Scholar]
  13. Holland E. G., Taylor A. T. Glucocorticoids in clinical practice. J Fam Pract. 1991 May;32(5):512–519. [PubMed] [Google Scholar]
  14. Hougardy D. M., Peterson G. M., Bleasel M. D., Randall C. T. Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther. 2000 Jun;25(3):227–234. doi: 10.1046/j.1365-2710.2000.00284.x. [DOI] [PubMed] [Google Scholar]
  15. Hough S., Teitelbaum S. L., Bergfeld M. A., Avioli L. V. Isolated skeletal involvement in Cushing's syndrome: response to therapy. J Clin Endocrinol Metab. 1981 May;52(5):1033–1038. doi: 10.1210/jcem-52-5-1033. [DOI] [PubMed] [Google Scholar]
  16. Khosla S., Lufkin E. G., Hodgson S. F., Fitzpatrick L. A., Melton L. J., 3rd Epidemiology and clinical features of osteoporosis in young individuals. Bone. 1994 Sep-Oct;15(5):551–555. doi: 10.1016/8756-3282(94)90280-1. [DOI] [PubMed] [Google Scholar]
  17. McEvoy C. E., Ensrud K. E., Bender E., Genant H. K., Yu W., Griffith J. M., Niewoehner D. E. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):704–709. doi: 10.1164/ajrccm.157.3.9703080. [DOI] [PubMed] [Google Scholar]
  18. Peat I. D., Healy S., Reid D. M., Ralston S. H. Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis. 1995 Jan;54(1):66–68. doi: 10.1136/ard.54.1.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Peel N. F., Moore D. J., Barrington N. A., Bax D. E., Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis. 1995 Oct;54(10):801–806. doi: 10.1136/ard.54.10.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Prummel M. F., Wiersinga W. M., Lips P., Sanders G. T., Sauerwein H. P. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab. 1991 Feb;72(2):382–386. doi: 10.1210/jcem-72-2-382. [DOI] [PubMed] [Google Scholar]
  21. Reid I. R. Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Jun;14(2):279–298. doi: 10.1053/beem.2000.0074. [DOI] [PubMed] [Google Scholar]
  22. Verstraeten A., Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis. 1986 Oct;45(10):852–857. doi: 10.1136/ard.45.10.852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Walsh L. J., Wong C. A., Pringle M., Tattersfield A. E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996 Aug 10;313(7053):344–346. doi: 10.1136/bmj.313.7053.344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. van Staa T. P., Leufkens H. G., Abenhaim L., Begaud B., Zhang B., Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000 Feb;93(2):105–111. doi: 10.1093/qjmed/93.2.105. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES